1. Home
  2. Browse
  3. HRA012460
HRA012460
   HRA012460.xlsx
Title:
Integrating ctDNA Dynamics and Sequential Organoid Drug Screening: A Novel Strategy to Enhance Breast Cancer Treatment Efficacy
Release date:
2025-08-01
Description:
As dynamic changes in circulating tumor DNA (ctDNA) variant allele frequency (VAF) reflect real-time therapeutic efficacy, timely treatment modification guided by rising ctDNA VAF, combined with sequential organoid drug screening, may enable precision selection of optimized regimens to counteract evolving resistance in breast cancer. This study presents a novel therapeutic approach by integrating ctDNA dynamics with sequential organoid drug screening to optimize breast cancer treatment. We performed targeted deep sequencing on plasma samples from 71 breast cancer patients, revealing that ctDNA clearance correlates with improved disease-free survival. Additionally, we established 40 breast cancer organoid models, demonstrating the potential of organoid culture supernatants for comprehensive mutation profiling and drug sensitivity testing.
Data Accessibility:   
Controlled access Request Data
BioProject:
PRJCA042933
Study type:
Disease Study
Disease name:
female breast cancer
Data Access Committee

For each controlled access study, there is a corresponding Data Access Committee(DAC) to determine the access permissions. Access to actual data files is not managed by NGDC.


DAC NO.:
HDAC002477
DAC name:
Zhang Xianyu Research Group
Contact person:
Zhang Xianyu
Email:
zhangxianyu@ems.hrbmu.edu.cn
Description:
Zhang Xianyu Research Group of Harbin Medical University Cancer Hospital
Individuals & samples
Files
Request Data
Submitter:   Zhang Xianyu / zhangxianyu@ems.hrbmu.edu.cn
Organization:   Harbin Medical University Cancer Hospital
Submission date:   2025-07-10
Requests:   -